Welcome to our dedicated page for Kraig Biocraft Laboratories SEC filings (Ticker: KBLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kraig Biocraft Laboratories's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kraig Biocraft Laboratories's regulatory disclosures and financial reporting.
Kraig Biocraft Laboratories, Inc. reported no revenue for the three and six months ended June 30, 2026 and remains a development-stage company focused on recombinant spider silk fibers. The company posted a net loss of $909,535 for the quarter and $1,852,255 for the six months, compared with losses of $726,133 and $1,326,166 in the prior-year periods.
Cash and cash equivalents increased to $3,391,646 from $1,790,236 at December 31, 2025, primarily from raising $2,772,547 via a Standby Equity Purchase Agreement. Operating cash used was $1,128,413 for the six months. The balance sheet shows total assets of $4,271,792 and a stockholders’ deficit of $(6,751,116), improved from $(7,998,958) at year-end, but the company still has a working capital deficiency of $7,326,899.
Management explicitly states that these deficits and continued cash burn raise substantial doubt about the ability to continue as a going concern. The company carries a related-party note payable of $1,492,000 and related-party accounts payable and accrued expenses of $8,767,002, including accrued CEO salary and interest. Kraig also holds $440,652 in gold bullion and $3,281,516 in a government money market fund at fair value, and has expanded leasing and production commitments in Vietnam through multiple long-term operating leases.
Registration of 207,787,193 shares of Class A common stock is added via a Prospectus Supplement dated May 22, 2026. The supplement updates the April 30, 2026 prospectus and must be read together with that prospectus.
The company’s Form 10-Q included with the supplement shows 1,113,049,449 shares outstanding as of May 14, 2026, cash and cash equivalents of $2,890,990, and a net loss of $(942,720) for the three months ended March 31, 2026. The filing discloses a going concern qualification due to working capital and stockholders’ deficiencies and notes efforts to raise additional capital.
Kraig Biocraft Laboratories, Inc. registers 306,124,163 shares of Class A Common Stock pursuant to a Prospectus Supplement dated May 22, 2026.
The Prospectus Supplement supplements the Prospectus dated May 14, 2026. As context, shares outstanding were 1,113,049,449 Class A shares as of May 14, 2026. The Company reported a net loss of $(942,720) for the three months ended March 31, 2026 and a working capital deficiency of $(7,666,616), and the financials include a going concern note.
Kraig Biocraft Laboratories, Inc. files a Prospectus Supplement dated May 22, 2026 registering 306,124,163 shares of Class A common stock. The supplement updates the Prospectus dated May 14, 2026 and incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026.
The Form 10-Q shows $2,890,990 in cash as of March 31, 2026, a net loss of $942,720 for the three months ended March 31, 2026, and 1,113,049,449 shares outstanding as of May 14, 2026. Management discloses a working capital deficiency of $7,666,616 and states substantial doubt about going concern.
Kraig Biocraft Laboratories reported first‑quarter 2026 results with no revenue and a net loss of $942,720, wider than the prior‑year quarter. Operating expenses reached $825,500, driven by general and administrative costs, officer salary, professional fees and higher research and development spending.
Cash and cash equivalents increased to $2,890,990 as of March 31, 2026, mainly from $1,644,588 raised under a Standby Equity Purchase Agreement, for which 16,581,603 new shares were issued. Despite the stronger cash balance, the company had a working capital deficiency of $7,666,616, a stockholders’ deficit of $7,061,674 and total liabilities of $10,783,506 against assets of $3,721,832. Management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
Kraig Biocraft Laboratories has registered 306,124,163 shares of Class A common stock for resale by selling shareholders. The registration covers shares underlying secured convertible notes and warrants from Yorkville transactions, and the Company will not receive proceeds from resale; it will receive cash only if warrants are exercised.
The prospectus states 1,113,049,449 shares outstanding as of May 14, 2026 and discloses a Standby Equity Purchase Agreement providing the Company the right to sell up to $10,000,000 of common stock to an investor subject to conditions and a 4.99% beneficial ownership limit on any single investor.
Kraig Biocraft Laboratories, Inc. is registering 306,124,163 shares of Class A common stock for resale by selling shareholders, consisting primarily of shares underlying Yorkville convertible notes and warrants. The company is not selling any shares here and will receive no proceeds from resales; it will only receive cash if warrants are exercised.
The prospectus states shares outstanding were 1,113,049,449 as of May 14, 2026 and the OTCQB last sale price was $0.1442 per share (May 8, 2026). The registration covers resale methods under the plan of distribution and terminates when the registered shares are sold or may be sold under Rule 144.
Kraig Biocraft Laboratories, Inc. registers 306,124,163 shares of Class A Common Stock for resale by selling shareholders pursuant to post-effective amendments to its Form S-1.
This prospectus covers resale shares underlying convertible notes and multiple warrants; the Company is not selling any shares here and will receive no proceeds from the selling shareholders' sales, although it would receive cash if the warrants are exercised. The filing also discloses a going concern qualification in the independent auditor's report and states 1,113,049,449 shares issued and outstanding as of May 11, 2026.
Kraig Biocraft Laboratories, Inc. registers for resale up to 207,787,193 shares of Common Stock by YA II PN, Ltd. under a standby equity purchase agreement (SEPA) that permits the company to sell up to $10,000,000 of Common Stock to the investor over a 36-month term. The filing states 1,081,471 Commitment Shares were issued and that 51,443,697 shares have been sold under the SEPA for aggregate gross proceeds of $4,524,430. The company will bear registration expenses; the Selling Stockholder will bear selling commissions. The prospectus notes potential dilution, trading overhang, a going concern qualification in the 2025 and 2024 auditor reports, and that there are 1,106,033,465 shares issued and outstanding as of April 30, 2026.